TCThomas M. Conlon

Thomas M. Conlon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas M. Conlon has a total of 303 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New approaches to uncover COPD pathobiology and develop therapies

    by Yohannes Tesfaigzi, Ali Önder Yildirim, Francesca Polverino, Thomas M. Conlon, Venkataramana Sidhaye, Maor Sauler, S. Vamsee Raju, Renata Z. Jurkowska, Divay Chandra, Michael H. Cho, et al.

    Chronic obstructive pulmonary disease (COPD) was the third leading cause of global mortality in 2011 but receives limited attention and research funding. This Review describes the current knowledge on COPD risk factors, including genetic and epigenetic determinants and their interactions with the microbiome and environmental exposures. Preclinical models are being refined and single-cell transcriptomic, metabolomic, and proteomic technologies are being implemented to investigate the molecular mechanisms of disease progression. Patient cohorts to define biomarkers of early disease and the latest approaches to diagnose pre-COPD are essential to accelerate the development of novel and effective therapeutic interventions and translate new findings into clinical trials. This Review is a summary of topics covered by a symposium organized by the COPD-iNET consortium, an international network of researchers who have established a platform that facilitates collaboration of this multidisciplinary group of preclinical, translational, and clinical researchers.


  • Top Cited Papers

    Small Airway Disease in Pre-Chronic Obstructive Pulmonary Disease with Emphysema: A Cross-Sectional Study

    by Stijn E. Verleden, Jeroen M. H. Hendriks, Annemiek Snoeckx, Cindy Mai, Yves Mentens, Wim Callebaut, Bruno De Belie, Paul E. Van Schil, Veronique Verplancke, Annelies Janssens, et al.

    Rationale: Small airway disease is an important pathophysiological feature of chronic obstructive pulmonary disease (COPD). Recently, “pre-COPD” has been put forward as a potential precursor stage of COPD that is defined by abnormal spirometry findings or significant emphysema on computed tomography (CT) in the absence of airflow obstruction. Objective: To determine the degree and nature of (small) airway disease in pre-COPD using microCT in a cohort of explant lobes/lungs. Methods: We collected whole lungs/lung lobes from patients with emphysematous pre-COPD (n = 10); Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I (n = 6), II (n = 6), and III/IV (n = 7) COPD; and controls (n = 10), which were analyzed using CT and microCT. The degree of emphysema and the number and morphology of small airways were compared between groups, and further correlations were investigated with physiologic measures. Airway and parenchymal pathology was also validated with histopathology. Measurements and Main Results: The numbers of transitional bronchioles and terminal bronchioles per milliliter of lung were significantly lower in pre-COPD and GOLD stages I, II, and III/IV COPD compared with controls. In addition, the number of alveolar attachments of the transitional bronchioles and terminal bronchioles was also lower in pre-COPD and all COPD groups compared with controls. We did not find any differences between the pre-COPD and COPD groups in CT or microCT measures. The percentage of emphysema on CT showed the strongest correlation with the number of small airways in the COPD groups. Histopathology showed an increase in the mean chord length and a decrease in alveolar surface density in pre-COPD and all GOLD COPD stages compared with controls. Conclusions: Lungs of patients with emphysematous pre-COPD already show fewer small airways and airway remodeling even in the absence of physiologic airway obstruction.


  • Oxysterol metabolism dictates macrophage influx during SARS-CoV-2 infection

    by Thomas M. Conlon, Ali Önder Yildirim

    Oxysterol metabolism offers an exciting novel angle to freshly consider when elucidating the molecular mechanisms underlying lung disease and lung infection.https://bit.ly/3xnZx0C


  • Open Access

    A transcriptomics-guided drug target discovery strategy identifies receptor ligands for lung regeneration

    by Xinhui Wu, I. Sophie T. Bos, Thomas M. Conlon, Meshal Ansari, Vicky Verschut, Luke van der Koog, Lars A. Verkleij, Angela D’aMbrosi, Aleksey Matveyenko, Herbert B. Schiller, et al.

    Currently, there is no pharmacological treatment targeting defective tissue repair in chronic disease. Here, we used a transcriptomics-guided drug target discovery strategy using gene signatures of smoking-associated chronic obstructive pulmonary disease (COPD) and from mice chronically exposed to cigarette smoke, identifying druggable targets expressed in alveolar epithelial progenitors, of which we screened the function in lung organoids. We found several drug targets with regenerative potential, of which EP and IP prostanoid receptor ligands had the most profound therapeutic potential in restoring cigarette smoke–induced defects in alveolar epithelial progenitors in vitro and in vivo. Mechanistically, we found, using single-cell RNA sequencing analysis, that circadian clock and cell cycle/apoptosis signaling pathways were differentially expressed in alveolar epithelial progenitor cells in patients with COPD and in a relevant model of COPD, which was prevented by prostaglandin E2 or prostacyclin mimetics. We conclude that specific targeting of EP and IP receptors offers therapeutic potential for injury to repair in COPD.


  • Top Cited Papers
    Open Access

    The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD

    by Gizem Günes Günsel, Thomas M. Conlon, Aicha Jeridi, Rinho Kim, Zeynep Ertüz, Niklas J. Lang, Meshal Ansari, Mariia Novikova, Dongsheng Jiang, Maximilian Strunz, et al.

    Extravasation of monocytes into tissue and to the site of injury is a fundamental immunological process, which requires rapid responses via post translational modifications (PTM) of proteins. Protein arginine methyltransferase 7 (PRMT7) is an epigenetic factor that has the capacity to mono-methylate histones on arginine residues. Here we show that in chronic obstructive pulmonary disease (COPD) patients, PRMT7 expression is elevated in the lung tissue and localized to the macrophages. In mouse models of COPD, lung fibrosis and skin injury, reduced expression of PRMT7 associates with decreased recruitment of monocytes to the site of injury and hence less severe symptoms. Mechanistically, activation of NF-κB/RelA in monocytes induces PRMT7 transcription and consequential mono-methylation of histones at the regulatory elements of RAP1A, which leads to increased transcription of this gene that is responsible for adhesion and migration of monocytes. Persistent monocyte-derived macrophage accumulation leads to ALOX5 over-expression and accumulation of its metabolite LTB4, which triggers expression of ACSL4 a ferroptosis promoting gene in lung epithelial cells. Conclusively, inhibition of arginine mono-methylation might offer targeted intervention in monocyte-driven inflammatory conditions that lead to extensive tissue damage if left untreated.


  • Open Access

    Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice

    by Barbara Spix, Elisabeth S. Butz, Cheng-Chang Chen, Anna Scotto Rosato, Rachel Tang, Aicha Jeridi, Veronika Kudrina, Eva Plesch, Philipp Wartenberg, Elisabeth Arlt, et al.

    Lung emphysema and chronic bronchitis are the two most common causes of chronic obstructive pulmonary disease. Excess macrophage elastase MMP-12, which is predominantly secreted from alveolar macrophages, is known to mediate the development of lung injury and emphysema. Here, we discovered the endolysosomal cation channel mucolipin 3 (TRPML3) as a regulator of MMP-12 reuptake from broncho-alveolar fluid, driving in two independently generated Trpml3−/− mouse models enlarged lung injury, which is further exacerbated after elastase or tobacco smoke treatment. Mechanistically, using a Trpml3IRES-Cre/eR26-τGFP reporter mouse model, transcriptomics, and endolysosomal patch-clamp experiments, we show that in the lung TRPML3 is almost exclusively expressed in alveolar macrophages, where its loss leads to defects in early endosomal trafficking and endocytosis of MMP-12. Our findings suggest that TRPML3 represents a key regulator of MMP-12 clearance by alveolar macrophages and may serve as therapeutic target for emphysema and chronic obstructive pulmonary disease.


  • Epigenetic regulation via PRMT7 controls monocyte migration and COPD pathogenesis

    by Thomas Conlon, Gizem Gunes, Aicha Jeridi, Rin Kim, Gerald Burgstaller, Stijn Verleden, Tobias Stöger, Gunnar Dittmar, Melanie Königshoff, Oliver Eickelberg, et al.

    COPD is an inflammatory lung disease characterized by progressive airflow limitation and tissue destruction. Cigarette smoke (CS) is a major risk factor for the development of the disease but only 15% of smokers develop disease which suggests a potential role for epigenetic regulation in disease pathogenesis. Histone methylation by protein arginine methyltransferases (PRMTs) is one of the most important epigenetic controls and implicated in immune system dysfunction and inflammation. Here we investigate the role of arginine methylation as an important determinant of monocyte-driven inflammatory responses in COPD. PRMT7 expression is increased in COPD patients (1.3 fold with P<0.01) compared to non-diseased smokers and localized mainly in macrophages. Using CS-induced animal models of COPD, we observed that mice with reduced expression of Prmt7 demonstrated impaired recruitment of macrophages to the lungs by 40% compared to WT animals following CS-exposure which prevented emphysema development (airspace enlargement 22µm vs 26µm, P<0.01) and improved diffusion capacity (56% vs 61%). Moreover, this impaired recruitment in macrophages protected against alveolar epithelial cell death. Mechanistically, we discovered that PRMT7 induced methylation of histones, in particular, H3R2me1 and H3R2me2, at enhancers regulating Rap1a expression, which is crucial for MAPK signaling, integrin activation, and the subsequent adhesion and migration ability of monocytes. In summary, we demonstrate that PRMT7 is upregulated in COPD patients compared to non-diseased smokers and regulates histone epigenetic marks controlling recruitment of monocyte-derived macrophages to the lungs and subsequent COPD immunopathogenesis.

  • Therapeutic targeting of iBALT induces lung regeneration in COPD

    by T Conlon, G John-Schuster, G Günes, A Jeridi, Z Ertüz, M Lehmann, R Costa, Y Hu, C Ciminieri, M Ansari, et al.

    Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with limited therapeutic options available, and no treatment able to reverse disease progression. Importantly, immune cells infiltrating the COPD lung are organized into inducible bronchus-associated lymphoid tissue (iBALT), which drives emphysema progression in humans and mice. iBALT formation requires the interaction of lymphotoxin β receptor (LTβR) on stromal organizer cells with TNF superfamily members lymphotoxin α (LTα) and β (LTβ). Here we investigate the therapeutic potential of iBALT-blockade in COPD pathogenesis. Gene set enrichment analysis (GSEA) of transcriptomics data and qPCR of an independent cohort revealed enrichment of the LTβR signaling pathway in the lungs of COPD patients resulting in increased expression of chemokines like CXCL13. Similar to COPD patients, mice chronically exposed to CS demonstrated iBALT generation and emphysema. Interestingly, LTβR-Ig treatment impaired CS-induced iBALT generation concomitant with the down regulation of chemokines like Cxcl13 and Ccl19. Remarkably, this led to full reversal of emphysema and regression of CS-mediated airway remodeling, which was accompanied by improvement in muscle wasting a prominent comorbidity of COPD. Mechanistically, lung restoration by LTβR-signalling-blockade was accompanied by increased Wnt/beta-catenin signal activity, which was crucial for lung epithelial regeneration. Of physiological relevance, this was validated in primary alveolar epithelial cells, human lung organoids and 3D human precision cut lung slices. Our findings pave the way for therapeutically exploiting the LTβR signalling pathway as a novel approach for activating Wnt signalling and tissue regeneration in chronic inflammatory diseases.

  • Publisher Correction: Inhibition of LTβR signalling activates WNT-induced regeneration in lung

    by Thomas M. Conlon, Gerrit John-Schuster, Danijela Heide, Dominik Pfister, Mareike Lehmann, Yan Hu, Zeynep Ertüz, Martin A. Lopez, Meshal Ansari, Maximilian Strunz, et al.